EMILIA supports Roche's T-DM1 filing but MARIANNE will be key to market performance
This article was originally published in Scrip
Roche is planning to file this year for US and EU approval of T-DM1, the antibody drug conjugate version of its breast cancer drug Herceptin, following positive top-line results from a Phase III trial. While the news is welcome, a key uncertainty remains regarding the drug's commercial potential: how it will stack up against Herceptin (trastuzumab) itself. Overall survival data are also yet to be reported.